STATEMENT OF NEED
Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population. About 20% of patients have invasive triple-negative breast cancer (TNBC), which is defined as having estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negativity. Whereas therapies targeting these receptors have demonstrated efficacy in other breast cancer subtypes, patients with TNBC are instead typically treated with standard chemotherapy, which does not always prove to be effective. While there have been advances with adjuvant chemotherapy, patients with TNBC still have a poorer prognosis than do patients who present with HR-positive or HER2-positive disease; for those with metastatic TNBC, the estimated median overall survival is only 13 months.
Medical oncologists, surgical oncologists, radiation oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
Upon completion of this activity, participants should be able to:
Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.
Sara M. Tolaney, MD, MPH (Chairperson)
Assistant Professor of Medicine
Harvard Medical School
Sara A. Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
There is no fee to participate in or claim CME/CE credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Continuing Nursing Education
i3 Health is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/CE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners and managers have nothing to disclose.
Sara M. Tolaney, MD, MPH discloses that she has served as a consultant for AstraZeneca, Eisai, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer, and Tesaro. She has served on the advisory board for AstraZeneca, Celldex, Eisai, Genentech/Roche, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer, Puma, and Sanofi. She has also received research support from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Lilly, Merck, Nanostring, Nektar, Novartis, and Pfizer.
Sara A. Hurvitz, MD discloses that she has received research support from Ambryx, Amgen, Bayer, BI Pharma, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Macrogenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, PUMA, Roche, and Seattle Genetics.
Peer reviewer, Manuel Pereira Herrera, MD, MEE, has nothing to disclose. Peer reviewer, Janice Farmorca Tran, PhD, RN, NP-C, AOCNP, CBCN, discloses that she has served on the speakers' bureau for Novartis. Nurse reviewer, Tammy Krogh, MSN, RN, OCN, has nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Eisai.
Aggregate participant data will be shared with commercial supporters of this activity.